Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system

Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system

Summary: Background: With the increased use of immune checkpoint inhibitors (ICIs) in advanced lung cancer, adverse events (AEs), particularly immune-related AEs (irAEs), have garnered considerable interest. We conducted a comprehensive assessment of the toxicity profile in advanced lung cancer usi...

Full description

Bibliographic Details
Main Authors: Yi-Dan Yan, Ying Zhao, Chi Zhang, Jie Fu, Ying-Jie Su, Xiang-Li Cui, Er-Li Ma, Bing-Long Liu, Zhi-Chun Gu, Hou-Wen Lin
Format: Article
Language:English
Published: Elsevier 2022-08-01
Series:EClinicalMedicine
Subjects:
Immune checkpoint inhibitors
Drug adverse events
Lung cancer
Pharmacovigilance
Data mining
Real-world data
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537022002656

Internet

http://www.sciencedirect.com/science/article/pii/S2589537022002656

Similar Items